Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Biotechnology & Medical Research

Delayed Nasdaq 09:49:24 2024-03-28 am EDT 5-day change 1st Jan Change
2.291 USD +2.29% Intraday chart for Eterna Therapeutics Inc. -1.64% +27.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Inflation -2- DJ
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors CI
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee CI
Eterna Therapeutics Inc. Announces Management Changes CI
Eterna Therapeutics Inc Announces Chief Executive Officer Changes, Effective January 1, 2024 CI
Eterna Therapeutics Inc Appoints Sanjeev Luther as President and Member of the Board of Directors, Effective January 1, 2024 CI
Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board CI
Eterna Therapeutics Selling $9.2 Million of Convertible Promissory Notes, Accompanying Warrants MT
Eterna Therapeutics Inc. announced that it expects to receive $9.2 million in funding CI
Eterna Therapeutics Inc. announced that it has received $1.5 million in funding CI
Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited CI
Eterna Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Eterna Therapeutics Inc. Appoints James Bristol to Its Board of Directors CI
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer MT
Gregory Fiore Resigns from Eterna Therapeutics Inc.'s Board of Directors CI
Lineage Cell Therapeutics, Inc. Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics CI
Eterna Therapeutics Inc. Appoints Ms. Dorothy J. Clarke as Director, Effective on August 28, 2023 CI
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Eterna Therapeutics Inc. Announces Management Changes CI
Eterna Therapeutics Inc. announced that it has received $8.715 million in funding CI
Eterna Therapeutics Inc. Announces Board Changes CI
Eterna Therapeutics Inc.(NasdaqCM:ERNA) dropped from Russell 3000E Index CI
Eterna Therapeutics Inc.(NasdaqCM:ERNA) dropped from Russell Microcap Value Index CI
Eterna Therapeutics Inc.(NasdaqCM:ERNA) dropped from Russell Microcap Index CI
Chart Eterna Therapeutics Inc.
More charts
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
More about the company
  1. Stock
  2. Equities
  3. Stock Eterna Therapeutics Inc. - Nasdaq
  4. News Eterna Therapeutics Inc.
  5. Brooklyn ImmunoTherapeutics : Sets Up Massachusetts Facility to Pursue Gene Editing, Cellular Therapies